These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 ligase mechanism and regulation. Lechtenberg BC; Rajput A; Sanishvili R; Dobaczewska MK; Ware CF; Mace PD; Riedl SJ Nature; 2016 Jan; 529(7587):546-50. PubMed ID: 26789245 [TBL] [Abstract][Full Text] [Related]
29. In vitro protein ubiquitination assay. Zhao Q; Liu L; Xie Q Methods Mol Biol; 2012; 876():163-72. PubMed ID: 22576094 [TBL] [Abstract][Full Text] [Related]
30. DNA Damage-Induced Foci of E2 Ubiquitin-Conjugating Enzyme are Detectable upon Co-transfection with an Interacting E3 Ubiquitin Ligase. Wang D; Tian Y; Wei D; Jing Y; Niu H; Xie K; Song Y Biochem Genet; 2016 Apr; 54(2):147-57. PubMed ID: 26718580 [TBL] [Abstract][Full Text] [Related]
31. A patent review of the ubiquitin ligase system: 2015-2018. Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221 [TBL] [Abstract][Full Text] [Related]
32. Targeting the ubiquitin pathway for cancer treatment. Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052 [TBL] [Abstract][Full Text] [Related]
33. The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy. Wang X; Zhang Y; Wu Y; Cheng H; Wang X Front Immunol; 2023; 14():1202633. PubMed ID: 37215134 [TBL] [Abstract][Full Text] [Related]
34. UFMylation: A Unique & Fashionable Modification for Life. Wei Y; Xu X Genomics Proteomics Bioinformatics; 2016 Jun; 14(3):140-146. PubMed ID: 27212118 [TBL] [Abstract][Full Text] [Related]
35. New insights into ubiquitin E3 ligase mechanism. Berndsen CE; Wolberger C Nat Struct Mol Biol; 2014 Apr; 21(4):301-7. PubMed ID: 24699078 [TBL] [Abstract][Full Text] [Related]
36. E3 ubiquitin ligases as cancer targets and biomarkers. Sun Y Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947 [TBL] [Abstract][Full Text] [Related]
39. Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases. Jeong Y; Oh AR; Jung YH; Gi H; Kim YU; Kim K Exp Mol Med; 2023 Oct; 55(10):2097-2104. PubMed ID: 37779139 [TBL] [Abstract][Full Text] [Related]
40. Two different classes of E2 ubiquitin-conjugating enzymes are required for the mono-ubiquitination of proteins and elongation by polyubiquitin chains with a specific topology. Windheim M; Peggie M; Cohen P Biochem J; 2008 Feb; 409(3):723-9. PubMed ID: 18042044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]